Literature DB >> 24656415

Amyotrophic lateral sclerosis developing during adalimumab therapy for psoriatic arthritis.

A Bougea1, E Anagnostou2, E Stamboulis2, E Kararizou2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24656415     DOI： 10.1016/j.neurol.2013.11.004

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN： 0035-3787            Impact factor:   2.607


× No keyword cloud information.
  3 in total

1.  Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System.

Authors:  Anna Gaimari; Michele Fusaroli; Emanuel Raschi; Elisa Baldin; Luca Vignatelli; Francesco Nonino; Fabrizio De Ponti; Jessica Mandrioli; Elisabetta Poluzzi
Journal:  Drug Saf       Date:  2022-05-24       Impact factor: 5.606

Review 2.  Psoriasis and neurodegenerative diseases-a review.

Authors:  Julia Nowowiejska; Anna Baran; Iwona Flisiak
Journal:  Front Mol Neurosci       Date:  2022-09-26       Impact factor: 6.261

Review 3.  Immune Modulation in the Treatment of Amyotrophic Lateral Sclerosis: A Review of Clinical Trials.

Authors:  Syed I Khalid; Leonel Ampie; Ryan Kelly; Shafeeq S Ladha; Christopher Dardis
Journal:  Front Neurol       Date:  2017-09-25       Impact factor: 4.003
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.